Given the definitive relationship between oncogenic BCR-ABL and the occurrence of Ph+ leukemia, effective degradation of this fusion protein, rather than the inhibition of tyrosine kinase activity, would be a favorable choice to overcome a series of drawbacks of small molecule inhibitors. This evidence concerns the gene BCR and leukemia.